FDA approves Ellipses’ application for advanced RET-altered cancer treatment

FDA approves Ellipses’ application for advanced RET-altered cancer treatment

Submitted by admin on June 23, 2022 - 10:52am
Source: 
Pharmaceutical Business Review
News Tags: 
Ellipses Pharma
EP0031
FDA
RET-altered cancer
Headline: 
FDA approves Ellipses’ application for advanced RET-altered cancer treatment
snippet: 

The US Food and Drug Administration (FDA) has approved Ellipses Pharma’s investigational new drug (IND) application for EP0031 (A400) to treat advanced RET-altered cancers.

Do Not Allow Advertisers to Use My Personal information